Moleculin Stock Analysis

MBRX -  USA Stock  

USD 1.46  0.07  5.04%

Moleculin Biotech CS price slide over the last few months may encourage investors to take a closer look at the firm as it is trading at a share price of 1.46 on 46,900 in trading volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in May. However, diversifying your holdings with Moleculin Biotech or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.93. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Moleculin Biotech partners.
Additionally, see Stocks Correlation.
The Moleculin Biotech stock analysis report makes it easy to digest most publicly released information about Moleculin Biotech and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Moleculin Stock analysis module also helps to analyze the Moleculin Biotech price relationship with some important fundamental indicators such as market cap and management efficiency.

Moleculin Stock Analysis Notes

About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moleculin Biotech recorded a loss per share of 0.7. The entity had not issued any dividends in recent years. The firm had a split on the 1st of February 2021. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Moleculin Biotech CS contact the company at 713 300 5160 or learn more at

Moleculin Biotech Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Moleculin Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Moleculin Biotech CS or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Moleculin Biotech generated a negative expected return over the last 90 days
Moleculin Biotech may become a speculative penny stock
Moleculin Biotech has high historical volatility and very poor performance
Net Loss for the year was (15.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Moleculin Biotech CS currently holds about 70.9 M in cash with (18.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Moleculin Biotech has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Yan Joy of 15000 shares of Moleculin Biotech subject to Rule 16b-3

Moleculin Biotech Upcoming and Recent Events

Earnings reports are used by Moleculin Biotech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moleculin Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Moleculin Largest EPS Surprises

Earnings surprises can significantly impact Moleculin Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Moleculin Biotech SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Moleculin Biotech prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Moleculin Biotech investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Moleculin Biotech specific information freely available to individual and institutional investors to make a timely investment decision.
16th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
9th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
31st of May 2022
Submission of Matters to a Vote of Security Holders
26th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure
20th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure
12th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure
5th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure

Moleculin Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 41.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moleculin Biotech's market, we take the total number of its shares issued and multiply it by Moleculin Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Moleculin Profitablity

Moleculin Biotech's profitability indicators refer to fundamental financial ratios that showcase Moleculin Biotech's ability to generate income relative to its revenue or operating costs. If, let's say, Moleculin Biotech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Moleculin Biotech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Moleculin Biotech's profitability requires more research than a typical breakdown of Moleculin Biotech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.17) (0.19) 
Return on Average Equity(0.19) (0.21) 
Return on Invested Capital 12.21  12.52 
Return on Sales(7.74) (8.35) 

Management Efficiency

The entity has return on total asset (ROA) of (25.38) % which means that it has lost $25.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (32.85) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech management efficiency ratios could be used to measure how well moleculin biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 12.52 in 2022, whereas Return on Average Assets are likely to drop (0.19)  in 2022. Moleculin Biotech Total Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets of 84.09 Million in 2021. Current Assets is likely to rise to about 78.2 M in 2022, whereas Goodwill and Intangible Assets are likely to drop slightly above 10 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 2.94  3.01 
Enterprise Value over EBIT 1.00  1.08 
Enterprise Value over EBITDA 1.40  1.50 
Price to Book Value 0.67  0.69 
Tangible Assets Book Value per Share 2.71  2.63 
Enterprise Value-21.9 M-22.5 M
Tangible Asset Value72.9 M78.7 M

Technical Drivers

As of the 26th of June, Moleculin Biotech secures the mean deviation of 3.03, and Risk Adjusted Performance of 0.0049. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moleculin Biotech, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Moleculin Biotech, which can be compared to its peers in the industry. Please verify Moleculin Biotech coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Moleculin Biotech CS is priced some-what accurately, providing market reflects its recent price of 1.46 per share. Please also check out Moleculin Biotech total risk alpha, which is currently at 0.4275 to check the company can sustain itself at a future point.

Moleculin Biotech Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Moleculin Biotech changes than the simple moving average.

Moleculin Biotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moleculin Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moleculin Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moleculin Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Moleculin Biotech Predictive Daily Indicators

Moleculin Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Moleculin Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Moleculin Biotech Forecast Models

Moleculin Biotech time-series forecasting models is one of many Moleculin Biotech's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moleculin Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Moleculin Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Moleculin Biotech stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Moleculin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Moleculin Biotech. By using and applying Moleculin Stock analysis, traders can create a robust methodology for identifying Moleculin entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(7.35) (7.93) 
Gross Margin 0.90  0.89 
Profit Margin(7.92) (8.54) 
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Moleculin Biotech to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Valuation Now


Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.7 M
Return On Assets
Return On Equity
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.